Enlivex to invest $212 million in crypto treasury fundraising using the Rain token
Date: 2025-11-25 Author: Henry Casey Categories: BUSINESS
Publicly traded Enlivex Therapeutics has announced its intention to raise $212 million through private investment, planning to use the entire proceeds to build its own crypto treasury. The underlying asset of the future reserve will be the Rain token (RAIN), which the company views as a promising instrument in the emerging prediction market sector.
The Rain project is positioned as a fully decentralized protocol operating on the Arbitrum network and designed to create markets where users can trade based on predictions generated by artificial intelligence algorithms. The token operates a buyback and burn mechanism, creating a sustainable economic model and cementing its role in the project's ecosystem.
According to Enlivex, the protocol's open architecture makes Rain a fundamental infrastructure for the prediction markets segment, which is demonstrating stable growth and increasingly attracting the attention of institutional investors. The company is aiming to enter the early stages of Rain's development, anticipating long-term returns.
Under the terms of the agreement, Enlivex will issue 212 million shares at a price of $1 per share. The transaction is expected to close by November 25, 2025. The company emphasized that the acquisition of Rain tokens will be conducted exclusively on open exchanges and through liquidity providers; there will be no interaction with the project team.
The Rain Foundation, in turn, will provide a grant aimed at maintaining the initial mNAV of approximately 0.95. Furthermore, Enlivex will receive the right to acquire an additional token supply worth up to $918 million.
The company's management notes that its investment strategy in DAT assets is not aimed at predicting short-term price fluctuations. The project was recommended by a banking consultant, and the parties had no prior working relationship. Following the final closing of the deal, Matteo Renzi, former Prime Minister of Italy, will be appointed to Enlivex's board of directors.
Despite its ambitious plans to create a digital treasury, the company continues to focus on its core business—the development of Allocetra, a drug for the treatment of osteoarthritis currently in late-stage clinical trials.
It was previously reported that Romanian authorities added Polymarket to its official blacklist for operating without a license.
